Overview
Location
United States, Texas, Southlake
Employees
11-50
Phone
+1 737-414-9213
Founded date
2008
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 12, 2024 | HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes | |
| Mar 6, 2024 | HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology | |
| Aug 21, 2023 | HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio | European Patent Allowed for Quantification by an ECG of Key Heart Measures using AI Heart Test Laboratories, an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier de... |
| May 10, 2023 | HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG | Heart Test Laboratories, d/b/a HeartSciences (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through the early detection of heart disease, ... |
| Feb 6, 2023 | HeartSciences Granted Key Israeli International Patent for its MyoVista Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease | Heart Test Laboratories, . d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), announced it ha... |
| Jan 24, 2023 | Q4 Was Digital Health’s Worst Quarter for Funding in 5 Years | In 2020 and 2021, investors were taking risks amid low interest rates and there was a mammoth influx of investment dollars into startups. They were willing to pay more amid high valuations to get a piece of innovative healthcare businesses.... |
| Nov 13, 2022 | HeartSciences’ MyoVista Technology Used to Develop AI-ECG Algorithm to Identify Patients | Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification Heart Test Laboratories, d/b/a HeartSciences , a medical technology company focused on saving lives by m... |
Reviews 0
FAQ about HeartSciences (NASDAQ:HSCS)
When was HeartSciences (NASDAQ:HSCS) founded?
HeartSciences (NASDAQ:HSCS) was founded in 2008.
What has the press written about HeartSciences (NASDAQ:HSCS)?
Parsers VC has collected 8 articles mentioning HeartSciences (NASDAQ:HSCS), among them “HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients wit...” (Mar 12, 2024) and “HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology” (Mar 6, 2024).
Is HeartSciences (NASDAQ:HSCS) still active?
Yes, HeartSciences (NASDAQ:HSCS) is active; its latest activity on Parsers VC dates from Oct 6, 2026.